Division of Nephrology, Department of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
Int Urol Nephrol. 2019 Jun;51(6):975-985. doi: 10.1007/s11255-019-02092-7. Epub 2019 Apr 15.
Henoch-Schönlein purpura nephritis (HSPN) is the most severe symptom of Henoch-Schönlein purpura. The role of immunosuppressive agents combined with steroids is controversial in treating HSPN. Our meta-analysis was performed to assess the efficacy and safety of the combined therapy in the treatment of HSPN compared with steroids alone.
Cochrane Library, Pubmed, Embase, and Web of Science were searched and Newcastle-Ottawa Scale was used to assess the quality of the literatures. Odds ratios (OR) and standard mean difference (SMD) with a 95% confidence interval (CI) were used for dichotomous and continuous variables. A random-effect model or fixed-effect analysis was applied according to heterogeneity.
A total of 9 articles were selected in our study. HSPN patients treated with combined therapy demonstrated a significant increase in complete remission rates (OR = 1.95; 95% CI 1.17-3.23, P = 0.010) and total remission rates (OR = 2.30 95% CI 1.33-3.98, P = 0.003) when compared with steroids alone. Children seemed to benefit more from combined treatment (OR = 2.45; CI 1.20-5.02, P = 0.014) than adults (OR = 1.56; CI 0.76-3.20, P = 0.225). Additionally, immunosuppressants plus steroids had an advantage on decreasing proteinuria (SMD = 0.28; CI 0.05-0.52, P = 0.019) and increasing the level of serum albumin (SMD = 0.98; CI 0.35-1.60, P = 0.002). However, significant differences were not found in the estimated glomerular filtration rate (eGFR) and rates of side-effects.
Administration of immunosuppressive agents combined with steroids may be a superior alternative for HSPN. Nevertheless, long-term, high-quality, large-sample, and multicenter RCTs are required to make the results more convincing.
过敏性紫癜肾炎(HSPN)是过敏性紫癜最严重的症状。免疫抑制剂联合激素治疗 HSPN 的疗效存在争议。我们的荟萃分析旨在评估与单独使用激素相比,联合治疗在治疗 HSPN 中的疗效和安全性。
我们检索了 Cochrane Library、Pubmed、Embase 和 Web of Science,并使用纽卡斯尔-渥太华量表评估文献质量。二分类变量采用比值比(OR)和标准化均数差(SMD)及其 95%置信区间(CI)表示,连续性变量采用固定或随机效应模型分析。
本研究共纳入 9 项研究。与单独使用激素相比,联合治疗组 HSPN 患者完全缓解率(OR=1.95;95%CI 1.17-3.23,P=0.010)和总缓解率(OR=2.30;95%CI 1.33-3.98,P=0.003)显著升高。儿童似乎比成人更受益于联合治疗(OR=2.45;95%CI 1.20-5.02,P=0.014),而非成人(OR=1.56;95%CI 0.76-3.20,P=0.225)。此外,免疫抑制剂联合激素在降低蛋白尿(SMD=0.28;95%CI 0.05-0.52,P=0.019)和提高血清白蛋白水平(SMD=0.98;95%CI 0.35-1.60,P=0.002)方面具有优势。然而,在估计肾小球滤过率(eGFR)和不良反应发生率方面未发现显著差异。
免疫抑制剂联合激素治疗可能是 HSPN 的一种更好的选择。然而,需要进行长期、高质量、大样本和多中心 RCT 以提高结果的可信度。